{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T06:07:36Z","timestamp":1789193256483,"version":"build-2803163510"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T00:00:00Z","timestamp":1789171200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T00:00:00Z","timestamp":1789171200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100015087","name":"Markey Cancer Center, University of Kentucky","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015087","id-type":"DOI","asserted-by":"publisher"}]},{"name":"NIH","award":["R37 AI052218"],"award-info":[{"award-number":["R37 AI052218"]}]},{"name":"USDA-NIFACBGP","award":["2023-38821-39584"],"award-info":[{"award-number":["2023-38821-39584"]}]},{"DOI":"10.13039\/100006108","name":"National Center for Advancing Translational Sciences","doi-asserted-by":"publisher","award":["UL1TR001998"],"award-info":[{"award-number":["UL1TR001998"]}],"id":[{"id":"10.13039\/100006108","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Kentucky Medical Services Foundation Chair in Pharmacy"},{"DOI":"10.13039\/100019888","name":"College of Pharmacy, University of Kentucky","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100019888","id-type":"DOI","asserted-by":"publisher"}]},{"name":"NIH\/NCI","award":["R01CA243529"],"award-info":[{"award-number":["R01CA243529"]}]},{"DOI":"10.13039\/100012524","name":"American Lebanese Syrian Associated Charities","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100012524","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Chemother Pharmacol"],"DOI":"10.1007\/s00280-026-04947-0","type":"journal-article","created":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T05:12:02Z","timestamp":1789189922000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Bridging tumor growth dynamics and survival in preclinical oncology drug development \u2013 a Tumor Growth Inhibition and Time-to-Event (TGI-TTE) modeling framework"],"prefix":"10.1007","volume":"96","author":[{"given":"Kumar Kulldeep","family":"Niloy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jamie","family":"Horn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nazmul Hasan","family":"Bhuiyan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suhas S","family":"Bhosale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khaled A","family":"Shaaban","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas E","family":"Prisinzano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jon S","family":"Thorson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jurgen","family":"Rohr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4314-4533","authenticated-orcid":false,"given":"Markos","family":"Leggas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,12]]},"reference":[{"issue":"3","key":"4947_CR1","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1007\/s10928-025-09970-x","volume":"52","author":"D Ronchi","year":"2025","unstructured":"Ronchi D, Tosca EM, Magni P (2025) Predicting tumor dynamics in treated patients from patient-derived-xenograft mouse models: a translational model-based approach. J Pharmacokinet Pharmacodyn 52(3):24. https:\/\/doi.org\/10.1007\/s10928-025-09970-x","journal-title":"J Pharmacokinet Pharmacodyn"},{"key":"4947_CR2","doi-asserted-by":"crossref","unstructured":"Niloy KK, Leggas M (2024) Preclinical tumor growth inhibition modeling and simulation to support dosing regimen selection of a novel EWS-FLI1 inhibitor for Ewing sarcoma treatment. American Conference of Pharmacometrics","DOI":"10.70534\/BSPJ3041"},{"issue":"1","key":"4947_CR3","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1007\/s00280-021-04370-7","volume":"89","author":"EM Tosca","year":"2022","unstructured":"Tosca EM, Terranova N, Stuyckens K, Dosne AG, Perera T, Vialard J, King P, Verhulst T, Perez-Ruixo JJ, Magni P, Poggesi I (2022) A translational model-based approach to inform the choice of the dose in phase 1 oncology trials: the case study of erdafitinib. Cancer Chemother Pharmacol 89(1):117\u2013128. https:\/\/doi.org\/10.1007\/s00280-021-04370-7","journal-title":"Cancer Chemother Pharmacol"},{"issue":"11","key":"4947_CR4","doi-asserted-by":"publisher","first-page":"1626","DOI":"10.1002\/psp4.12910","volume":"12","author":"EM Tosca","year":"2023","unstructured":"Tosca EM, Borella E, Piana C, Bouchene S, Merlino G, Fiascarelli A, Mazzei P, Magni P (2023) Model-based prediction of effective target exposure for MEN1611 in combination with trastuzumab in HER2-positive advanced or metastatic breast cancer patients. CPT: pharmacometrics Syst Pharmacol 12(11):1626\u20131639. https:\/\/doi.org\/10.1002\/psp4.12910","journal-title":"CPT: pharmacometrics Syst Pharmacol"},{"issue":"4","key":"4947_CR5","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1007\/s00280-023-04625-5","volume":"93","author":"S Kobuchi","year":"2024","unstructured":"Kobuchi S, Morita A, Jonan S, Amagase K, Ito Y (2024) Translational PK-PD\/TD modeling of antitumor effects and peripheral neuropathy in gemcitabine and nab-paclitaxel chemotherapy from xenograft mice to patients for optimal dose and schedule. Cancer Chemother Pharmacol 93(4):365\u2013379. https:\/\/doi.org\/10.1007\/s00280-023-04625-5","journal-title":"Cancer Chemother Pharmacol"},{"issue":"5","key":"4947_CR6","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1208\/s12248-024-00960-4","volume":"26","author":"EM Tosca","year":"2024","unstructured":"Tosca EM, Ronchi D, Rocchetti M, Magni P (2024) Predicting Tumor Volume Doubling Time and Progression-Free Survival in Untreated Patients from Patient-Derived-Xenograft (PDX) Models: A Translational Model-Based Approach. AAPS J 26(5):92. https:\/\/doi.org\/10.1208\/s12248-024-00960-4","journal-title":"AAPS J"},{"issue":"8","key":"4947_CR7","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1080\/17460441.2017.1340271","volume":"12","author":"L Carrara","year":"2017","unstructured":"Carrara L, Lavezzi SM, Borella E, De Nicolao G, Magni P, Poggesi I (2017) Current mathematical models for cancer drug discovery. Expert Opin Drug Discov 12(8):785\u2013799. https:\/\/doi.org\/10.1080\/17460441.2017.1340271","journal-title":"Expert Opin Drug Discov"},{"issue":"4","key":"4947_CR8","doi-asserted-by":"publisher","first-page":"820","DOI":"10.1158\/0008-5472.Can-19-0811","volume":"80","author":"EM Tosca","year":"2020","unstructured":"Tosca EM, Rocchetti M, Pesenti E, Magni P (2020) A Tumor-in-Host DEB-Based Approach for Modeling Cachexia and Bevacizumab Resistance. Cancer Res 80(4):820\u2013831. https:\/\/doi.org\/10.1158\/0008-5472.Can-19-0811","journal-title":"Cancer Res"},{"issue":"3","key":"4947_CR9","doi-asserted-by":"publisher","first-page":"1094","DOI":"10.1158\/0008-5472.can-03-2524","volume":"64","author":"M Simeoni","year":"2004","unstructured":"Simeoni M, Magni P, Cammia C, De Nicolao G, Croci V, Pesenti E, Germani M, Poggesi I, Rocchetti M (2004) Predictive pharmacokinetic-pharmacodynamic modeling of tumor growth kinetics in xenograft models after administration of anticancer agents. Cancer Res 64(3):1094\u20131101. https:\/\/doi.org\/10.1158\/0008-5472.can-03-2524","journal-title":"Cancer Res"},{"issue":"2","key":"4947_CR10","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1007\/s10928-009-9117-9","volume":"36","author":"G Koch","year":"2009","unstructured":"Koch G, Walz A, Lahu G, Schropp J (2009) Modeling of tumor growth and anticancer effects of combination therapy. J Pharmacokinet Pharmacodyn 36(2):179\u2013197. https:\/\/doi.org\/10.1007\/s10928-009-9117-9","journal-title":"J Pharmacokinet Pharmacodyn"},{"issue":"7","key":"4947_CR11","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1158\/1535-7163.Mct-23-0471","volume":"23","author":"F Meric-Bernstam","year":"2024","unstructured":"Meric-Bernstam F, Lloyd MW, Koc S, Evrard YA, McShane LM, Lewis MT, Evans KW, Li D, Rubinstein L, Welm A, Dean DA 2nd, Srivastava A, Grover JW, Ha MJ, Chen H, Huang X, Varadarajan K, Wang J, Roth JA, Welm B, Govinden R, Ding L, Kaochar S, Mitsiades N, Carvajal-Carmona L, Herylyn M, Davies MA, Shapiro GI, Fields R, Trevino JG, Harrell JC, Doroshow JH, Chuang JH, Moscow JA (2024) Assessment of Patient-Derived Xenograft Growth and Antitumor Activity: The NCI PDXNet Consensus Recommendations. Mol Cancer Ther 23(7):924\u2013938. https:\/\/doi.org\/10.1158\/1535-7163.Mct-23-0471","journal-title":"Mol Cancer Ther"},{"issue":"3","key":"4947_CR12","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1007\/s00280-023-04558-z","volume":"92","author":"N Kassir","year":"2023","unstructured":"Kassir N, Chan P, Dang S, Bruno R (2023) External validation of a tumor growth inhibition-overall survival model in non-small-cell lung cancer based on atezolizumab studies using alectinib data. Cancer Chemother Pharmacol 92(3):205\u2013210. https:\/\/doi.org\/10.1007\/s00280-023-04558-z","journal-title":"Cancer Chemother Pharmacol"},{"issue":"1","key":"4947_CR13","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1007\/s00280-016-3059-x","volume":"78","author":"EC Martin","year":"2016","unstructured":"Martin EC, Aarons L, Yates JW (2016) Accounting for dropout in xenografted tumour efficacy studies: integrated endpoint analysis, reduced bias and better use of animals. Cancer Chemother Pharmacol 78(1):131\u2013141. https:\/\/doi.org\/10.1007\/s00280-016-3059-x","journal-title":"Cancer Chemother Pharmacol"},{"issue":"1","key":"4947_CR14","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1038\/s41572-018-0003-x","volume":"4","author":"TGP Gr\u00fcnewald","year":"2018","unstructured":"Gr\u00fcnewald TGP, Cidre-Aranaz F, Surdez D, Tomazou EM, de \u00c1lava E, Kovar H, Sorensen PH, Delattre O, Dirksen U (2018) Ewing sarcoma. Nat Rev Dis Primers 4(1):5. https:\/\/doi.org\/10.1038\/s41572-018-0003-x","journal-title":"Nat Rev Dis Primers"},{"issue":"2","key":"4947_CR15","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1056\/NEJMra2028910","volume":"384","author":"N Riggi","year":"2021","unstructured":"Riggi N, Suv\u00e0 ML, Stamenkovic I (2021) Ewing\u2019s Sarcoma. N Engl J Med 384(2):154\u2013164. https:\/\/doi.org\/10.1056\/NEJMra2028910","journal-title":"N Engl J Med"},{"key":"4947_CR16","doi-asserted-by":"publisher","unstructured":"Niloy KK, Horn J, Bhuiyan NH, Shaaban KA, Bhosale SS, Prisinzano TE, Thorson JS, Rohr J, Leggas M (2025) Preclinical Pharmacokinetic Evaluation of Mithramycin and Mithramycin SA Tryptophan-Conjugated Analog. Pharmaceutics 17(6). https:\/\/doi.org\/10.3390\/pharmaceutics17060765","DOI":"10.3390\/pharmaceutics17060765"},{"issue":"12Supplement","key":"4947_CR17","doi-asserted-by":"publisher","first-page":"B150","DOI":"10.1158\/1535-7163.Targ-23-b150","volume":"22","author":"M Leggas","year":"2023","unstructured":"Leggas M, Niloy KK, Yetirajam R, Horn J, Kazuto Y, Prisinzano TE, Thorson JS, Tsoikov O, Rohr J (2023) Abstract B150: Targeting EWS-FLI1 with mithramycin analogues for Ewing sarcoma treatment. Mol Cancer Ther 22(12Supplement):B150\u2013B150. https:\/\/doi.org\/10.1158\/1535-7163.Targ-23-b150","journal-title":"Mol Cancer Ther"},{"issue":"8Supplement1","key":"4947_CR18","doi-asserted-by":"publisher","first-page":"4360","DOI":"10.1158\/1538-7445.Am2025-4360","volume":"85","author":"R Yetirajam","year":"2025","unstructured":"Yetirajam R, Acharya S, Niloy KK, Kazuto Y, Horn J, Prisinzano T, Thorson JS, Tsodikov O, Rohr J, Leggas M (2025) Abstract 4360: Development of a novel mithramycin analogue with improved pharmacokinetics and therapeutic window for targeted inhibition of EWS-FLI1 in Ewing sarcoma. Cancer Res 85(8Supplement1):4360\u20134360. https:\/\/doi.org\/10.1158\/1538-7445.Am2025-4360","journal-title":"Cancer Res"},{"key":"4947_CR19","doi-asserted-by":"publisher","DOI":"10.21203\/rs.3.rs-9035594\/v1","author":"KK Niloy","year":"2026","unstructured":"Niloy KK, Horn J, Bhuiyan NH, Shaaban KA, Bhosale SS, Prisinzano TE, Thorson JS, Rohr J, Leggas M (2026) Nonlinear Mixed-Effects Modeling to Characterize the Pharmacokinetics of a Novel Mithramycin Analogue for Ewing Sarcoma in Mice. Res Square. https:\/\/doi.org\/10.21203\/rs.3.rs-9035594\/v1","journal-title":"Res Square"},{"key":"4947_CR20","doi-asserted-by":"publisher","first-page":"S5","DOI":"10.1002\/cpt.70201","volume":"119","author":"K Niloy","year":"2026","unstructured":"NiloyK, Leggas M (2026) Bridging Tumor Growth Dynamics and Survival in Preclinical Oncology Drug Development: A Translational Tumor Growth Inhibition and Time-to-Event (TGI-TTE) Modeling Framework.American Society for Clinical Pharmacology and Therapeutics. Clin Pharmacol Ther 119:S5\u2013S115. https:\/\/doi.org\/10.1002\/cpt.70201","journal-title":"Clin Pharmacol Ther"},{"issue":"9","key":"4947_CR21","doi-asserted-by":"publisher","first-page":"1256","DOI":"10.1002\/psp4.12841","volume":"11","author":"LK Fostvedt","year":"2022","unstructured":"Fostvedt LK, Nickens DJ, Tan W, Parivar K (2022) Tumor growth inhibition modeling to support the starting dose for dacomitinib. CPT: pharmacometrics Syst Pharmacol 11(9):1256\u20131267. https:\/\/doi.org\/10.1002\/psp4.12841","journal-title":"CPT: pharmacometrics Syst Pharmacol"},{"issue":"6","key":"4947_CR22","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.1002\/psp4.70002","volume":"14","author":"H Struemper","year":"2025","unstructured":"Struemper H, Rathi C, Muliaditan M, Goulooze SC, Franzese RC, Mantero A, Melhem M, Post TM, Visser SAG (2025) Development of a Joint Tumor Size-Overall Survival Modeling and Simulation Framework Supporting Oncology Development Decision-Making. CPT: pharmacometrics Syst Pharmacol 14(6):1006\u20131017. https:\/\/doi.org\/10.1002\/psp4.70002","journal-title":"CPT: pharmacometrics Syst Pharmacol"},{"issue":"6","key":"4947_CR23","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.1002\/psp4.13137","volume":"13","author":"M Marchand","year":"2024","unstructured":"Marchand M, Gon\u00e7alves A, Mercier F, Chanu P, Jin JY, Guedj J, Bruno R (2024) Tumor growth and overall survival modeling to support decision making in phase Ib\/II trials: A comparison of the joint and two-stage approaches. CPT: pharmacometrics Syst Pharmacol 13(6):1017\u20131028. https:\/\/doi.org\/10.1002\/psp4.13137","journal-title":"CPT: pharmacometrics Syst Pharmacol"},{"issue":"10","key":"4947_CR24","doi-asserted-by":"publisher","first-page":"1171","DOI":"10.1002\/psp4.12686","volume":"10","author":"P Chan","year":"2021","unstructured":"Chan P, Marchand M, Yoshida K, Vadhavkar S, Wang N, Lin A, Wu B, Ballinger M, Sternheim N, Jin JY, Bruno R (2021) Prediction of overall survival in patients across solid tumors following atezolizumab treatments: A tumor growth inhibition-overall survival modeling framework. CPT: pharmacometrics Syst Pharmacol 10(10):1171\u20131182. https:\/\/doi.org\/10.1002\/psp4.12686","journal-title":"CPT: pharmacometrics Syst Pharmacol"},{"issue":"3","key":"4947_CR25","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1002\/cpt.2953","volume":"114","author":"CS Shemesh","year":"2023","unstructured":"Shemesh CS, Chan P, Marchand M, Gon\u00e7alves A, Vadhavkar S, Wu B, Li C, Jin JY, Hack SP, Bruno R (2023) Early Decision Making in a Randomized Phase II Trial of Atezolizumab in Biliary Tract Cancer Using a Tumor Growth Inhibition-Survival Modeling Framework. Clin Pharmacol Ther 114(3):644\u2013651. https:\/\/doi.org\/10.1002\/cpt.2953","journal-title":"Clin Pharmacol Ther"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-026-04947-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00280-026-04947-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-026-04947-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T05:12:05Z","timestamp":1789189925000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00280-026-04947-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,12]]},"references-count":25,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4947"],"URL":"https:\/\/doi.org\/10.1007\/s00280-026-04947-0","relation":{},"ISSN":["1432-0843"],"issn-type":[{"value":"1432-0843","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,12]]},"assertion":[{"value":"13 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"M.L., J.S.T, K.A.S., and J.R. are inventors on patents and\/or patent applications related to mithramycin derivatives with anticancer activity. These intellectual property rights are assigned to the University of Kentucky. The other authors declare no competing interests.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"100"}}